Oculis Holding AG

NasdaqGM:OCS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🕶 Eyewear

💊 Pharmaceuticals

Location

Switzerland

Market Cap

USD 983.93 M

Share Price

USD 19.28

Avg Daily Volume

36,771

Change (1 day)

-1.03%

Change (1 year)

64.79%

Change (YTD)

13.41%

Oculis Holding AG Share Price on June 20, 2025: USD 19.28

Oculis Holding AG Share Price is USD 19.28 on June 20, 2025, a 64.79% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Oculis Holding AG 52-week low Share Price is USD 22.91 on June 20, 2025, which is 18.83% above the current Share Price.
Oculis Holding AG 52-week low Share Price is USD 10.94 on June 20, 2025, which is -43.26% below the current Share Price.
Oculis Holding AG average Share Price for the last 52 weeks is USD 16.37.

Daily

From:

To:

Zoom:

Key data

Date	Share Price	Share Price	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)

NasdaqGM: OCS

Oculis Holding AG

CEO	Dr. Riad Sherif M.B.A., M.D.
IPO Date	May 18, 2021
Location	Switzerland
Headquarters	Bahnhofstrasse 7
Employees	49
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🕶 Eyewear 💊 Pharmaceuticals

Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.